Stage-specific inhibition of MHC class I presentation by the epstein-barr virus BNLF2a protein during virus lytic cycle

PLoS Pathogens

Volumn 5, Issue 6, 2009, Pages

  Croft, Nathan P ^a   Shannon Lowe, Claire ^a   Bell, Andrew I ^a   Horst, Daniëlle ^b   Kremmer, Elisabeth ^c   Ressing, Maaike E ^b   Wiertz, Emmanuel J H J ^d   Middeldorp, Jaap M ^e   Rowe, Martin ^a   Rickinson, Alan B ^a   Hislop, Andrew D ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EARLY ANTIGEN; EPITOPE; IMMEDIATE EARLY PROTEIN; LATE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN BNLF2A; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS PROTEIN; BNLF21 PROTEIN, HUMAN HERPESVIRUS 4; HLA ANTIGEN; HLA ANTIGEN CLASS 1; MATRIX PROTEIN; MESSENGER RNA;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CD8+ T LYMPHOCYTE; CELL TRANSFORMATION; CONTROLLED STUDY; DOWN REGULATION; EPSTEIN BARR VIRUS; GENE DELETION; GENE EXPRESSION; IMMEDIATE EARLY GENE; LYMPHOCYTE CLONE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; UPREGULATION; VIRUS MUTANT; VIRUS PATHOGENESIS; VIRUS RECOMBINANT; VIRUS REPLICATION; WILD TYPE; ANIMAL; BIOSYNTHESIS; CELL LINE; FLOW CYTOMETRY; GENETICS; HUMAN; IMMUNOLOGY; MUTATION; POLYMERASE CHAIN REACTION; RAT; VIROLOGY; VIRUS INFECTION;

HERPESVIRIDAE; HUMAN HERPESVIRUS 4;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; EPSTEIN-BARR VIRUS INFECTIONS; FLOW CYTOMETRY; GENE EXPRESSION; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; RATS; RNA, MESSENGER; VIRAL MATRIX PROTEINS;

EID: 67650863635     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000490     Document Type: Article

References (40)

1. Stinchcombe JC, Griffiths GM (2003) The role of the secretory immunological synapse in killing by CD8+ CTL. Semin Immunol 15: 301-305.
2. Groothuis TA, Griekspoor AC, Neijssen JJ, Herberts CA, Neefjes JJ (2005) MHC class I alleles and their exploration of the antigen-processing machinery. Immunol Rev 207: 60-76. (Pubitemid 41415008)
3. Vossen MT, Westerhout EM, Soderberg-Naucler C, Wiertz EJ (2002) Viral immune evasion: a masterpiece of evolution. Immunogenetics 54: 527-542. (Pubitemid 35435511)
4. Lilley BN, Ploegh HL (2005) Viral modulation of antigen presentation: manipulation of cellular targets in the ER and beyond. Immunol Rev 207: 126-144.
5. Rickinson A, Kieff E (2007) Epstein-Barr virus. In: Knipe DM, Howley PM, eds. Fields Virology Philadelphia Walters Kluwer/Lippincott, Williams & Wilkins. pp 2655-2700.
6. Pudney VA, Leese AM, Rickinson AB, Hislop AD (2005) CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. J Exp Med 201: 349-360.
7. Keating S, Prince S, Jones M, Rowe M (2002) The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules. J Virol 76: 8179-8188. (Pubitemid 34809072)
8. Ressing ME, Keating SE, van Leeuwen D, Koppers-Lalic D, Pappworth IY, et al. (2005) Impaired transporter associated with antigen processing-dependent peptide transport during productive EBV infection. J Immunol 174: 6829-6838. (Pubitemid 40705646)
9. Hislop AD, Ressing ME, van Leeuwen D, Pudney VA, Horst D, et al. (2007) A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med 204: 1863-1873. (Pubitemid 47236322)
10. Feederle R, Kost M, Baumann M, Janz A, Drouet E, et al. (2000) The Epstein- Barr virus lytic program is controlled by the co-operative functions of two transactivators. Embo J 19: 3080-3089. (Pubitemid 30386778)
11. Lautscham G, Mayrhofer S, Taylor G, Haigh T, Leese A, et al. (2001) Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway. J Exp Med 194: 1053-1068. (Pubitemid 32995777)
12. Takada K, Ono Y (1989) Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J Virol 63: 445-449. (Pubitemid 19028127)
13. Yuan J, Cahir-McFarland E, Zhao B, Kieff E (2006) Virus and cell RNAs expressed during Epstein-Barr virus replication. J Virol 80: 2548-2565. (Pubitemid 43271560)
14. Yewdell JW, Nicchitta CV (2006) The DRiP hypothesis decennial: support, controversy, refinement and extension. Trends Immunol 27: 368-373.
15. Park B, Kim Y, Shin J, Lee S, Cho K, et al. (2004) Human cytomegalovirus inhibits tapasin-dependent peptide loading and optimization of the MHC class I peptide cargo for immune evasion. Immunity 20: 71-85. (Pubitemid 38134295)
16. Rowe M, Glaunsinger B, van Leeuwen D, Zuo J, Sweetman D, et al. (2007) Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. Proc Natl Acad Sci U S A 104: 3366-3371. (Pubitemid 46364165)
17. Zuo J, Thomas W, van Leeuwen D, Middeldorp JM, Wiertz EJ, et al. (2008) The DNase of gammaherpesviruses impairs recognition by virus-specific CD8+ T cells through an additional host shutoff function. J Virol 82: 2385-2393. (Pubitemid 351293539)
18. Zuo J, Currin A, Griffin BD, Shannon-Lowe C, Thomas WA, et al. (2009) The epstein-barr virus g-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog 5: e1000255. doi:10.1371/journal.ppat.1000255.
19. Munks MW, Pinto AK, Doom CM, Hill AB (2007) Viral interference with antigen presentation does not alter acute or chronic CD8 T cell immunodominance in murine cytomegalovirus infection. J Immunol 178: 7235-7241.
20. Gold MC, Munks MW, Wagner M, McMahon CW, Kelly A, et al. (2004) Murine cytomegalovirus interference with antigen presentation has little effect on the size or the effector memory phenotype of the CD8 T cell response. J Immunol 172: 6944-6953. (Pubitemid 38669134)
21. Bohm V, Simon CO, Podlech J, Seckert CK, Gendig D, et al. (2008) The immune evasion paradox: immunoevasins of murine cytomegalovirus enhance priming of CD8 T cells by preventing negative feedback regulation. J Virol 82: 11637-11650.
22. Stevenson PG, May JS, Smith XG, Marques S, Adler H, et al. (2002) K3- mediated evasion of CD8(+) T cells aids amplification of a latent gammaherpesvirus. Nat Immunol 3: 733-740. (Pubitemid 34884829)
23. Rivailler P, Jiang H, Cho YG, Quink C, Wang F (2002) Complete nucleotide sequence of the rhesus lymphocryptovirus: genetic validation for an Epstein-Barr virus animal model. J Virol 76: 421-426. (Pubitemid 33139028)
24. Biegalke BJ (1995) Regulation of human cytomegalovirus US3 gene transcription by a cis-repressive sequence. J Virol 69: 5362-5367.
25. Tenney DJ, Colberg-Poley AM (1991) Human cytomegalovirus UL36-38 and US3 immediate-early genes: temporally regulated expression of nuclear, cytoplasmic, and polysome-associated transcripts during infection. J Virol 65: 6724-6734.
26. Jones TR, Wiertz EJ, Sun L, Fish KN, Nelson JA, et al. (1996) Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc Natl Acad Sci U S A 93: 11327-11333. (Pubitemid 26347121)
27. Jones TR, Muzithras VP (1991) Fine mapping of transcripts expressed from the US6 gene family of human cytomegalovirus strain AD169. J Virol 65: 2024-2036.
28. Delecluse HJ, Hilsendegen T, Pich D, Zeidler R, Hammerschmidt W (1998) Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc Natl Acad Sci U S A 95: 8245-8250. (Pubitemid 28326098)
29. Steven NM, Annels NE, Kumar A, Leese AM, Kurilla MG, et al. (1997) Immediate early and early lytic cycle proteins are frequent targets of the Epstein- Barr virus-induced cytotoxic T cell response. J Exp Med 185: 1605-1617. (Pubitemid 27203257)
30. Bogedain C, Wolf H, Modrow S, Stuber G, Jilg W (1995) Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus. J Virol 69: 4872-4879.
31. Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB (2002) Epitopespecific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med 195: 893-905.
32. Saulquin X, Ibisch C, Peyrat MA, Scotet E, Hourmant M, et al. (2000) A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening. Eur J Immunol 30: 2531-2539.
33. Scotet E, David-Ameline J, Peyrat MA, Moreau-Aubry A, Pinczon D, et al. (1996) T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis. J Exp Med 184: 1791-1800. (Pubitemid 26404470)
34. Young LS, Lau R, Rowe M, Niedobitek G, Packham G, et al. (1991) Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia. J Virol 65: 2868-2874.
35. Buisson M, Manet E, Trescol-Biemont MC, Gruffat H, Durand B, et al. (1989) The Epstein-Barr virus (EBV) early protein EB2 is a posttranscriptional activator expressed under the control of EBV transcription factors EB1 and R. J Virol 63: 5276-5284. (Pubitemid 19278767)
36. Zhang JX, Chen HL, Zong YS, Chan KH, Nicholls J, et al. (1998) Epstein-Barr virus expression within keratinizing nasopharyngeal carcinoma. J Med Virol 55: 227-233. (Pubitemid 28270768)
37. Zeng Y, Middeldorp J, Madjar JJ, Ooka T (1997) A major DNA binding protein encoded by BALF2 open reading frame of Epstein-Barr virus (EBV) forms a complex with other EBV DNA-binding proteins: DNAase, EA-D, and DNA polymerase. Virology 239: 285-295. (Pubitemid 28105635)
38. Kishishita M, Luka J, Vroman B, Poduslo JF, Pearson GR (1984) Production of monoclonal antibody to a late intracellular Epstein-Barr virus-induced antigen. Virology 133: 363-375. (Pubitemid 14138020)
39. van Grunsven WM, van Heerde EC, de Haard HJ, Spaan WJ, Middeldorp JM (1993) Gene mapping and expression of two immunodominant Epstein-Barr virus capsid proteins. J Virol 67: 3908-3916.
40. Young L, Alfieri C, Hennessy K, Evans H, O'Hara C, et al. (1989) Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 321: 1080-1085. (Pubitemid 19256661)